ReviewEcancermedicalscience2017
The past and future of breast cancer treatment-from the papyrus to individualised treatment approaches.
Review in Ecancermedicalscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Combined breast conservation therapy versus mastectomy for BRCA mutation carriers - A systematic review and meta-analysis.Breast (Edinburgh, Scotland) · 2021Pooled it
- Long-term effectiveness and overdiagnosis in the NHS breast screening programme: a cohort study with up to 33 years of follow-up.British journal of cancer · 2026Article
- Association of Pretreatment Serum Albumin and Systemic Inflammatory Markers with Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer.Journal of clinical medicine · 2026Article
- Multi-Protein Profiling Reveals High Nuclear KFL-4 Expression as a Predictor of Poor Overall Survival in Breast Cancer: A Retrospective Cohort Study.International journal of molecular sciences · 2026Article
- Using [Cancers · 2025Article
- Photothermal manipulation of the fringing field in gold nanorod dimers towards the apoptosis of cancerous cells.Scientific reports · 2024Article
- Clinical Pharmacist-Led Interventions for Improving Breast Cancer Management-A Scoping Review.Current oncology (Toronto, Ont.) · 2024Article
- Presidential Address: A Long Time Ago in the Future.Annals of surgical oncology · 2023Article
- Changes in the survival of patients with breast cancer: Poland, 2000-2019.Breast cancer research and treatment · 2023Article
- A new perspective on the proper timing of radiotherapy during CDK4/6 inhibitor therapy in patients with "bone-only" metastatic breast cancer.Pathology oncology research : POR · 2023Review
- The effects of exercise training for eight weeks on immune cell characteristics among breast cancer survivors.Frontiers in sports and active living · 2023Article
- Decoding Insulin-Like Growth Factor Signaling Pathway From a Non-coding RNAs Perspective: A Step Towards Precision Oncology in Breast Cancer.Journal of mammary gland biology and neoplasia · 2022Review
- Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Genomics in Egypt: Current Status and Future Aspects.Frontiers in genetics · 2022Review
- Molecular Subtyping of Cancer Based on Robust Graph Neural Network and Multi-Omics Data Integration.Frontiers in genetics · 2022Article
- 100 Disruptive Publications in Breast Cancer Research.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Narrative review of theoretical considerations regarding HITHOC between past and future.Annals of translational medicine · 2021Review
- The Use of Real-World Evidence for Oral Chemotherapies in Breast Cancer.Journal of the advanced practitioner in oncology · 2021Review
- Chemotherapy Treatment Considerations in Metastatic Breast Cancer.Journal of the advanced practitioner in oncology · 2021Review
- Long Noncoding RNAs Regulate the Radioresistance of Breast Cancer.Analytical cellular pathology (Amsterdam) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the oldest diseases ever described, since ancient Egypt there have always been attempts to treat and cure this illness. The growing body of knowledge about breast cancer biology and improvements in surgical and medical treatments has been built over time with contributions from many talented and enthusiastic physicians and researchers. Medical advances have changed the approach from a previously incurable condition, into a surgical disease. Further improvements in cancer biology have allowed the development of systemic treatments, hormonal therapies, and targeted drugs. The description of the molecular intrinsic subtypes of breast cancer clarified the understanding of breast cancer as a group of heterogeneous diseases, associated with different clinical outcomes, and therapeutic opportunities. This paper reviews how breast cancer treatment has improved since the earliest descriptions, in ancient times, and how future approaches, such as gene signatures, molecular profiling, and liquid biopsies, aim to further develop individualised treatments and improve treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.